LAVIOLETTE PAUL A 4

What Happened
Paul A. Laviolette, CEO of Pulse Biosciences (PLSE), purchased 15,000 shares on May 11, 2026 at $19.69 per share for a total cost of $295,350. The transaction is reported as a purchase (code P) and represents an insider buy rather than a sale.

Key Details

• Transaction date: 2026-05-11; Price: $19.69; Shares: 15,000; Total value: $295,350.
• Transaction code: P (purchase).
• Shares were acquired through the company’s at‑the‑market (ATM) equity offering program under an Equity Distribution Agreement with TD Securities (USA) LLC.
• Footnotes: (1) Acquisition occurred under the ATM program and during an open trading window in compliance with applicable securities laws. (2) Shares were acquired in a negotiated manner at the prevailing market bid price or better.
• Shares owned after the transaction: not specified in the provided filing.
• Filing timeliness: Reported on 2026-05-11 (same date as transaction), indicating a timely Form 4 filing.

Context
Insider purchases can be viewed as a positive signal because executives are personally investing in company stock, though they do not prove future performance. This buy was executed via the company’s ATM program (a mechanism for issuing/selling shares into the market with a sales agent), rather than as an option exercise or gift.